Targeting the PI3K signaling pathway in cancer Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Neoplasms
  • Phosphatidylinositol 3-Kinases

abstract

  • The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human cancers, and inhibitors of this pathway are under active development as anti-cancer therapeutics. In this review, we discuss the data supporting the use of PI3K pathway inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy as single agents and in combination with other targeted therapies, specifically those targeting the MEK-ERK signaling pathway.

publication date

  • February 2010

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC2822054

Digital Object Identifier (DOI)

  • 10.1016/j.gde.2009.11.002

PubMed ID

  • 20006486

Additional Document Info

start page

  • 87

end page

  • 90

volume

  • 20

number

  • 1